FDA is alerting patients and health care professionals about the ...
WEB4 days ago — Pfizer Inc., the manufacturer of Oxbryta, announced it is voluntarily withdrawing the medication from the market, ceasing distribution, and discontinuing all active clinical trials and expanded ...
MARAC Statement: Pfizer’s Voxelotor (Oxbryta®) Withdrawal
WEB2 days ago — SCDAA Medical and Research Advisory Committee (MARAC) Statement: Voxelotor (Oxbryta®) 9/27/24. What is the news? Pfizer announced the withdrawal of voxelotor (Oxbryta®) from national and global markets on September 25, 2024. Clinical research was also stopped. “Pfizer’s decision is based …
Pfizer withdraws sickle-cell disease treatment | Reuters
WEB5 days ago — Pfizer bought Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022. ... Reuters, the news and media division of Thomson Reuters, is the world ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB5 days ago — Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer decision to withdrawal sickle cell drug leaves patients
WEB4 days ago — Sept. 26, 2024. Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB5 days ago — NEW YORK, September 25, 2024--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this ...
FDA alerts patients about Pfizer's Oxbryta withdrawal
WEB4 days ago — Sept 26 (Reuters) - The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's (PFE.N) sickle cell disease treatment Oxbryta ...
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB5 days ago — The drug was the centerpiece in Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics in 2022 during a post-COVID M&A spree for the drugmaker. At that time, Pfizer said Oxbryta and GBT ...
Pfizer voluntarily withdraws all lots of sickle cell disease treatment ...
WEBWalton Oaks, 25th September 2024 - Pfizer Inc announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB4 days ago — Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
- Some results have been removed